DocMorris Lifts 2025 Revenue 11% on Rx Surge and Digital Health Push

The latest announcement is out from DocMorris ( (CH:DOCM) ).

DocMorris reported that external revenue in 2025 rose 11.1% in local currencies to CHF 1.19 billion, with total revenue up 12.4%, driven by strong prescription (Rx) growth of 33.2%, a 7.1% increase in non-prescription (Non-Rx) sales, and triple-digit momentum in high-margin Digital Services such as TeleClinic, which more than doubled revenue. Growth accelerated in the fourth quarter across all segments, active customers climbed to 11.0 million despite the phase-out of the Zur Rose brand in Germany, and the company highlighted the rapid uptake of its AI Health Companion as a key element in scaling its digital health platform, while reiterating its path toward improved profitability with confirmed earnings guidance and a focus on reaching EBITDA and free cash flow breakeven over the next two years.

The most recent analyst rating on (CH:DOCM) stock is a Hold with a CHF6.50 price target. To see the full list of analyst forecasts on DocMorris stock, see the CH:DOCM Stock Forecast page.

More about DocMorris

Swiss-based DocMorris AG is a leading online pharmacy and digital health company, operating e-pharmacy, telemedicine and health marketplaces with strong brands in Germany and other European countries. Medicines and health products are mainly shipped from its automated logistics centre in Heerlen, Netherlands, while TeleClinic functions as Germany’s largest telemedicine platform, linking patients with more than 6,000 doctors. In Southern Europe, DocMorris runs leading online marketplaces for health and care products, serving 11 million active customers with around 1,600 employees, and its shares are listed on the SIX Swiss Exchange.

Average Trading Volume: 330,275

Technical Sentiment Signal: Sell

Current Market Cap: CHF319.3M

Find detailed analytics on DOCM stock on TipRanks’ Stock Analysis page.